FDA's Potency Assurance Guidance for Cell and Gene Therapy: What Canadian Sponsors Must Prepare

On 2 November 2026, the U.S. Food and Drug Administration issued final guidance for manufacturers of cellular and gene therapy (CGT) products, Potency Assurance for Cellular and Gene Therapy Products. The guidance replaces FDA's 2011 potency testing guidance for CGT products and asks sponsors to build potency assurance into every stage of a therapy's lifecycle, rather than treating potency as a single release test at the end.

For Canadian cell and gene therapy developers, this is not a foreign technicality. Many Canadian sponsors run their programs with an eye on the United States market and file with FDA, and Health Canada regulates the same products as biologic drugs with their own lot release expectations. A potency strategy that satisfies FDA's new thinking will also stand you in good stead with Health Canada's clinical trial framework. This article explains what the guidance asks for and how to prepare.

Executive summary

FDA's final guidance recommends a Potency Assurance Strategy that runs from early development through post approval. Instead of relying on one potency assay at release, sponsors are expected to control the factors that affect potency across the product lifecycle: variability in raw materials, testing during manufacturing, and laboratory tests that confirm each batch is biologically active. The approach is flexible and risk based, and it gives specialized attention to products with short shelf lives, viral vector gene therapies, and patient specific therapies.

What the potency assurance guidance is

It is FDA's recommendation for how CGT manufacturers should assure potency across development and commercialization. Potency, in biologics terms, is the measure that a product does what it is supposed to do therapeutically. The guidance provides FDA's recommendations for a Potency Assurance Strategy that guides manufacturers to test and verify, before a product reaches a patient, that every batch meets a defined standard of potency. It is guidance, so it describes FDA's current thinking and recommendations rather than binding rules, but it sits on top of the legal requirement that biologics be tested for potency.

Why it replaces the 2011 guidance. The cell and gene therapy field has moved well beyond where it was in 2011. Products now include autologous and patient specific therapies, viral vector gene therapies, and products with very short shelf lives, where a single end of line potency test can be impractical or uninformative. The new guidance reframes potency as something you assure through the whole process, not only at release.

What to do. Read the final guidance and compare it against your current potency control. Our note on FDA guidance on biosimilar post approval manufacturing changes shows how FDA increasingly expects a lifecycle, data driven view of product quality, and the same mindset applies here.

Why it matters for Canadian CGT and biologics sponsors

Canadian sponsors are affected through cross border filings and through Health Canada's own biologics expectations. If you intend to file an Investigational New Drug application or a Biologics License Application with FDA, your potency program will be reviewed against this guidance. Even for Canada only programs, Health Canada regulates cell and gene therapies as biologic drugs under the Food and Drug Regulations, and potency is part of lot release. Aligning early avoids rework later.

The commercial risk is real. Potency problems are a common reason for clinical holds, refuse to file actions, and post approval commitments. For small Canadian biotech teams, a weak potency strategy can delay a program by many months. Building the strategy early, while your process and assays are still flexible, is far cheaper than retrofitting it during a pre licence inspection.

What a Potency Assurance Strategy must cover

The strategy connects your product's biological function to specific, risk based controls at each lifecycle stage. FDA frames this as integrating potency considerations at every stage of development and commercialization. In practice, that means defining what your product is supposed to do, identifying the quality attributes that reflect that function, and building assays and controls that give you confidence in each batch. The table below is a practical way to organize the work.

Raw material variability, testing during manufacturing, and batch release

Three control points carry most of the weight in the guidance. First, raw materials. Cell and gene therapies depend on biologically variable inputs, so the guidance highlights controls for variability in raw materials. A strong supplier qualification and risk tiering programme and incoming specifications reduce the variability your process has to absorb.

Second, testing during manufacturing. In process measurements that correlate with potency let you catch problems before final product, which matters most when shelf life is short. These controls work hand in hand with solid batch failure and investigation practices under 21 CFR 211.192 when a result is out of expectation.

Third, batch release. Laboratory tests that confirm each batch is biologically active remain the backbone of release. Where a single assay cannot represent the full mechanism of action, a matrix of complementary assays is expected. Tie your release decisions to a clear deviation and out of specification investigation procedure so that marginal results are handled consistently.

Special cases: short shelf life, viral vectors, and patient specific products

The guidance gives specialized attention to the hardest potency problems in CGT. For products with short shelf lives, final potency results may not be available before administration, so the strategy must lean on in process controls, surrogate measures, and well understood process consistency. For viral vector gene therapies, potency often reflects both the vector and the expressed function, which can require more than one assay. For patient specific therapies, small and variable batches make assay robustness and a documented risk based rationale essential.

Risk management ties it together. A documented, risk based rationale is what lets a reviewer accept a strategy that does not look like a classic small molecule release test. The discipline of a risk management file along ISO 14971 lines translates well here: identify what could reduce potency, decide how you control and detect it, and keep the evidence.

Building the strategy step by step

A Potency Assurance Strategy is easier to build in a defined sequence than all at once. The following steps turn FDA's lifecycle expectation into a workable plan for a development team.

Step 1: Define the therapeutic function. Write down, in plain terms, what the product is meant to do in the patient and the biological mechanism behind it. Everything else flows from this.

Step 2: Identify potency relevant attributes. List the measurable quality attributes that reflect that function, and rank them by how strongly they relate to clinical activity.

Step 3: Design the assay or matrix. Choose assays that measure those attributes. If one assay cannot capture the mechanism, plan a matrix of complementary tests and document why.

Step 4: Control the inputs and the process. Set raw material specifications and in process controls that reduce and detect variability before final product, with attention to short shelf life constraints.

Step 5: Qualify, then validate. Qualify the assays for clinical use, then validate them for licensure, and justify specifications from a sufficient number of representative batches.

Step 6: Manage the lifecycle. Trend potency data, feed it into product quality reviews, and route any process or assay change through formal change control so the strategy stays current after approval.

What reviewers commonly flag on potency

Potency findings cluster around a few recurring themes. In our experience supporting biologics and advanced therapy programs, the most frequent gaps are a potency assay that measures a surrogate marker rather than the actual mechanism of action, specifications set from too few batches to be meaningful, and a release test that is not stability indicating, so a product can pass at release yet lose activity before use. Reviewers also probe whether in process controls genuinely correlate with final potency, and whether the sponsor can explain, with data, why its chosen controls are adequate. Each of these is easier to fix during development than during a pre licence review.

Aligning with Health Canada lot release

A single potency strategy can serve both FDA and Health Canada if you plan it that way. Health Canada regulates cell and gene therapies as biologic drugs, and potency is part of the lot release information expected for a biologic. Building your strategy to FDA's lifecycle model, with qualified assays, justified specifications, and a documented risk rationale, produces exactly the evidence a Canadian submission and inspection also need. Supporting disciplines help: a clear validation master plan keeps assay and process validation on schedule, and an annual product quality review gives you the trending that shows potency control is holding over time.

Potency assurance readiness checklist

• Biological function defined: you can state, in writing, what your product does therapeutically and how potency reflects it.
• Strategy documented: a Potency Assurance Strategy maps controls to each lifecycle stage.
• Assays fit the mechanism: your potency assays, singly or as a matrix, capture the product's mechanism of action.
• Raw material controls: supplier qualification and incoming specifications address biological variability.
• In process testing: measurements that correlate with potency are built into manufacturing.
• Release testing validated: potency methods are qualified for clinical use and validated for licensure, with justified specifications.
• Special cases addressed: short shelf life, viral vector, or patient specific issues have a documented, risk based rationale.
• Lifecycle management: trending and change control keep the strategy current after approval.

Common mistakes to avoid

• Leaving potency to the end. Designing a release assay late, after the process is fixed, is the single most common and costly error.
• One assay for a complex mechanism. If a product has more than one relevant function, a single assay rarely represents potency.
• Ignoring raw material variability. Uncontrolled biological inputs undermine even a good assay.
• No plan for short shelf life. Relying on a final result that arrives after administration is not a strategy.
• Weak risk rationale. Reviewers accept flexibility when it is justified and documented, not when it is assumed.
• Treating guidance as optional. It is nonbinding, but it reflects what reviewers will expect at IND, BLA and inspection.

Frequently asked questions

What does FDA's potency assurance guidance require for gene therapy?

The guidance recommends a Potency Assurance Strategy that integrates potency controls across the lifecycle: defining the biological function, controlling raw material variability, testing during manufacturing, and confirming through laboratory testing that each batch is biologically active. It is guidance, so it describes FDA's recommendations rather than binding rules.

Does the new guidance replace the 2011 potency guidance?

Yes. FDA states that the final Potency Assurance for Cellular and Gene Therapy Products guidance replaces its 2011 potency testing guidance for CGT products.

Is a single potency assay enough?

Not always. Where a product's mechanism of action cannot be captured by one test, FDA expects a matrix of complementary assays. The right number and type of assays depend on the product and should be justified with a risk based rationale.

How does this affect Canadian sponsors?

Canadian sponsors who file with FDA will be assessed against this guidance. Health Canada also regulates cell and gene therapies as biologic drugs, with potency controlled as part of lot release, so aligning your strategy supports both pathways.

When does the strategy need to be in place?

As early as possible. Potency relevant decisions are cheapest to make during process and analytical development, while the process and assays are still flexible. Waiting until licensure or inspection usually means expensive rework.

Is there training available on the guidance?

FDA scheduled a webinar on 10 December 2026 to help stakeholders understand and implement the guidance. Teams building a potency strategy should plan to attend or review the materials afterward.

How MFLRC can help

MFLRC helps cell and gene therapy and biologics sponsors build a defensible Potency Assurance Strategy. We support mechanism of action and quality attribute assessments, potency assay strategy and qualification planning, raw material and supplier controls, specification setting, and the risk based documentation reviewers expect. Our chemistry, manufacturing and controls and quality assurance services cover gap assessments, SOP development, validation planning, QAP support, audits, and GMP compliance across Canadian and cross border programs, so your potency program holds up at IND, BLA and inspection.

If you are developing a cell or gene therapy and want your potency strategy reviewed against FDA's new guidance before your next filing, we can help.

Conclusion

FDA's 2 November 2026 potency assurance guidance tells cell and gene therapy developers something practical: potency is assured across the whole process, not proven by one test at the end. Define what your product does, control the inputs and steps that affect it, and verify every batch is biologically active, with a risk based rationale for the hard cases. Sponsors who adopt that mindset early, in Canada and the United States alike, will move through development and inspection with far fewer surprises.

Sources and references

• FDA news release: FDA Provides Clarity to Support Cell and Gene Therapy Development and Quality, 2 November 2026
• FDA Guidance for Industry: Potency Assurance for Cellular and Gene Therapy Products
• FDA webinar: Potency Assurance for Cellular and Gene Therapy Products, 10 December 2026
• U.S. Code of Federal Regulations, 21 CFR 610.10 (Potency)
• ICH Q6B: Specifications for biotechnological and biological products